EUVIMEDEUVIMED entdecken
Fallbericht

Cerebral Venous Sinus Thrombosis with Hemorrhagic Transformation in a Patient with Immune Thrombocytopenia Treated with Eltrombopag: A Fatal Case Report

Dr. Prathap J, Dr. Jayaprakash Appajigol

International Journal of Drug Delivery Technology · 19.05.2026 · 16 (29s)

DOI: 10.25258/ijddt.16.29s.28 ↗

Kurz gefasst

Fallbericht in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 19.05.2026. Verfasst von Dr. Prathap J und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by immune-mediated platelet destruction and impaired platelet production. Thrombopoietin receptor agonists (TPO-RAs), including eltrombopag, are increasingly used in refractory ITP to raise platelet counts. Although bleeding is the predominant concern in ITP, paradoxical thrombotic complications, particularly cerebral venous sinus thrombosis (CVST), are rare but potentially fatal adverse events associated with TPO-RA therapy. Case Presentation: A 63-year-old woman with immune thrombocytopenia who developed cerebral venous sinus thrombosis with hemorrhagic venous infarction following treatment with eltrombopag. She presented with progressive headache, vomiting, focal neurological deficits, and altered sensorium. Neuroimaging revealed extensive cerebral venous thrombosis involving the left cerebral venous system with hemorrhagic transformation, associated subdural hematoma, and significant mass effect. Despite aggressive medical management, including platelet transfusions, corticosteroids, eltrombopag, and intensive care support, her neurological condition deteriorated. Emergency decompressive craniectomy was performed; however, the postoperative course was complicated by diffuse cerebral edema, worsening hemorrhagic venous infarction, and herniation, culminating in a fatal outcome. This case highlights the paradoxical risk of cerebral venous sinus thrombosis associated with eltrombopag therapy in patients with immune thrombocytopenia. Clinicians should maintain a high index of suspicion for thrombotic complications in ITP patients receiving TPO receptor agonists, particularly when new neurological symptoms develop. Early recognition, prompt neuroimaging, and multidisciplinary management are essential to improve outcomes.

Zitieren

APA

J, D. P., & Appajigol, D. J. (2026). Cerebral Venous Sinus Thrombosis with Hemorrhagic Transformation in a Patient with Immune Thrombocytopenia Treated with Eltrombopag: A Fatal Case Report. International Journal of Drug Delivery Technology, 16(29s). https://doi.org/10.25258/ijddt.16.29s.28

Vancouver

J DP, Appajigol DJ. Cerebral Venous Sinus Thrombosis with Hemorrhagic Transformation in a Patient with Immune Thrombocytopenia Treated with Eltrombopag: A Fatal Case Report. International Journal of Drug Delivery Technology. 2026;16(29s). doi:10.25258/ijddt.16.29s.28

BibTeX
@article{J2026,
  author = {J, Dr. Prathap and Appajigol, Dr. Jayaprakash},
  title = {Cerebral Venous Sinus Thrombosis with Hemorrhagic Transformation in a Patient with Immune Thrombocytopenia Treated with Eltrombopag: A Fatal Case Report},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {29s},
  doi = {10.25258/ijddt.16.29s.28}
}
Kostenlos starten →